Copy to clipboard 
MicroPort Orthopedics reported 1H22 orthopedic sales of $107.7 million, -2.2% compared to the first half of last year. Excluding the impact of foreign currency exchange, the company grew +2.4% vs. the prior period.
The company dealt with the impact of volume-based procurement on joint replacement implants and COVID lockdowns in its domestic Chinese market. MicroPort’s international markets performed well, particularly EMEA. The company’s MedialPivot Knee System has been a market share driver in international markets.
Chinese revenues declined sharply due to volume-based procurement (VBP) price reductions and the COVID situation. However, MicroPort’s market access increased dramatically under VBP. Its joint replacement products entered 140 new hospitals, a 10% increase in its national coverage. VBP also brought a major breakthrough for the company’s spine and trauma products with an additional 200 hospitals, nearly doubling its prior total.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $104.4 | $107.4 | ($3.0) | (2.8%) |
| Knees | $41.9 | $43.0 | ($1.1) | (2.5%) |
| Hips | $62.5 | $64.4 | ($2.0) | (3%) |
| Spine | $1.7 | $1.7 | $0.1 | 4.3% |
| Trauma | $1.6 | $1.1 | $0.5 | 46.7% |
| Total | $107.7 | $110.1 | ($2.4) | (2.2%) |
Orthopedic Sales by Geography
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $43.7 | $42.3 | $1.4 | 3.3% |
| OUS | $64.0 | $67.8 | ($3.8) | (5.6%) |
| EMEA | $30.4 | $24.7 | $5.7 | 23.1% |
| APAC | $24.6 | $34.6 | ($10.1) | (29%) |
| ROW | $9.0 | $8.5 | $0.6 | 6.5% |
| Total | $107.7 | $110.1 | ($2.4) | (2.2%) |
MicroPort Orthopedics reported 1H22 orthopedic sales of $107.7 million, -2.2% compared to the first half of last year. Excluding the impact of foreign currency exchange, the company grew +2.4% vs. the prior period.
The company dealt with the impact of volume-based procurement on joint replacement implants and COVID lockdowns in its...
MicroPort Orthopedics reported 1H22 orthopedic sales of $107.7 million, -2.2% compared to the first half of last year. Excluding the impact of foreign currency exchange, the company grew +2.4% vs. the prior period.
The company dealt with the impact of volume-based procurement on joint replacement implants and COVID lockdowns in its domestic Chinese market. MicroPort’s international markets performed well, particularly EMEA. The company’s MedialPivot Knee System has been a market share driver in international markets.
Chinese revenues declined sharply due to volume-based procurement (VBP) price reductions and the COVID situation. However, MicroPort’s market access increased dramatically under VBP. Its joint replacement products entered 140 new hospitals, a 10% increase in its national coverage. VBP also brought a major breakthrough for the company’s spine and trauma products with an additional 200 hospitals, nearly doubling its prior total.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $104.4 | $107.4 | ($3.0) | (2.8%) |
| Knees | $41.9 | $43.0 | ($1.1) | (2.5%) |
| Hips | $62.5 | $64.4 | ($2.0) | (3%) |
| Spine | $1.7 | $1.7 | $0.1 | 4.3% |
| Trauma | $1.6 | $1.1 | $0.5 | 46.7% |
| Total | $107.7 | $110.1 | ($2.4) | (2.2%) |
Orthopedic Sales by Geography
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $43.7 | $42.3 | $1.4 | 3.3% |
| OUS | $64.0 | $67.8 | ($3.8) | (5.6%) |
| EMEA | $30.4 | $24.7 | $5.7 | 23.1% |
| APAC | $24.6 | $34.6 | ($10.1) | (29%) |
| ROW | $9.0 | $8.5 | $0.6 | 6.5% |
| Total | $107.7 | $110.1 | ($2.4) | (2.2%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
